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Background
Rheumatoid arthritis (RA) and systemic lupus erythema-
tosus (SLE) commonly involve the cardiovascular system
and are associated with significant morbidity and mortal-
ity, driven by cardiovascular inflammation, microvascular
and diastolic dysfunction and fibrosis. Cardiovascular
magnetic resonance (CMR) can assess non-invasively car-
diac function, strain, ischaemia, altered vascular function,
perfusion, inflammation and fibrosis; magnetic resonance
spectroscopy (MRS) provides further insights into the
status of myocardial energetics and lipidosis. To date,
there have been no cardiovascular MRS studies in RA
and SLE patients. We hypothesised that RA and SLE
would be associated with impaired myocardial energetics
and lipidosis.
Methods
The study population consisted of 16 RA patients
(10 female; mean age 51 ± 13 years), 13 SLE patients
(13 female; mean age 43 ± 9 years) and 12 age- and sex-
matched controls (8 female; mean age 49 ± 15 years).
Patients with previously known cardiovascular disease
(CVD) were excluded. Participants underwent CMR at
1.5T and the assessments included cine, tagging, T1
mapping, T2-weighted, perfusion, late gadolinium
(0.15mmol/kg gadoteric acid - Dotarem®) imaging and
ECV quantification. Further assessments included
proton (1H) and phosphorous (31P) MRS at 3T. Comor-
bid status, disease activity index and duration of disease
were recorded for each subject.
Results
Patients were well-matched with controls for sex, age and
comorbidity (Table 1). The DAS28-CRP was 5 ± 1 in RA
and the SLEDAI was 7 (4-11), respectively, indicating on-
going disease activity. There were no differences in left
ventricular (LV) size, mass and systolic function between
RA and SLE patients when compared to controls (Table
2). Consistent with previously described findings, there
were significant differences in strain, and tissue character-
istics between the patients and controls. The PCr/ATP
ratio was reduced in patients and measured 2.0 ± 0.3, 1.5
± 0.3 and 1.4 ± 0.3 (p=0.02) in controls, RA and SLE,
respectively. No differences were found in cardiac lipid
content when RA and SLE patients were compared to
controls. PCr/ATP ratio correlated with presence of LGE
(R -0.38, p=0.14), MPRI (R 0.61, p<0.001), LA size (R
-0.32, p=0.04), ECV (R -0.46, p=0.006) and volume frac-
tion of T1 >990ms (R -0.73, p<0.001).
Conclusions
In RA and SLE patients (with no overt cardiovascular
disease) myocardial energetics are impaired, likely due
to abnormal mitochondrial dysfunction. Abnormal myo-
cardial energetics are associated with indices of
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Table 1 Baseline characteristics
Controls N=12 RA N=16 SLE N=13 P value
Female sex, n (%) 8 (67) 10 (63) 13 (100) 0.05
Age, years 49 ± 15 51 ± 13 43 ± 9 0.18
Hypertension, n (%) 0 3 (19) 2 (16) -
Diabetes, n (%) 0 0 1 (8) -
Hyperlipidaemia, n (%) 0 3 (19) 0 -
BMI, kg/m2 24 ± 3 25 ± 3 27 ± 5 0.12
Chloroquine, n (%) N/A 11 (69) 11 (85) -
Methotrexate, n (%) N/A 15 (94) 1 (8) -
Prednisolone, n (%) N/A 2 (13) 9 (69) -
Leflunomide, n (%) N/A 3 (19) 1 (8) -
Sulfasalazine, n (%) N/A 3 (19) 0 -
Azathioprine, n (%) N/A 0 4 (31) -
Rituximab, n (%) N/A 2 (13) 1 (8) -
DAS28-CRP N/A 5 ± 1 N/A -
SLEDAI (median, IQR) N/A N/A 7 (4-11) -
ESR, mm/hr (median, IQR) N/A 7 (5-10) 10 (4-16) -
CRP, mg/L (median, IQR) 1 (1-1) 5 (2-7) 4 (2-6) <0.001
Duration of disease, years (median, IQR) N/A 11 (7-14) 13 (6-16) -
Duration of DMARDs, years (median, IQR) N/A 7 (5-11) 8 (3-11) -
Continuous data are mean ± SD unless otherwise indicated. Categorical data are frequency (percent) unless otherwise indicated. BMI, body mass index; CRP, C-
reactive protein; DAS28-CRP (rheumatoid arthritis disease activity index incorporating 28 swollen and tender joint count as well as the C-reactive protein); ESR,
erythrocyte sedimentation rate; IQR, interquartile range; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus
disease activity index
Table 2 CMR and MRS findings
Controls N=12 RA N=16 SLE N=13 P value
LVEDV indexed to BSA, ml/m2 78 ± 15 79 ± 23 74 ± 13 0.54
LVESV indexed to BSA, ml/m2 23 ± 5 23 ± 11 21 ± 6 0.75
LVEF, % 72 ± 4 72 ± 7 72 ± 5 0.96
LV Mass indexed to BSA, g/m2 53 ± 14 55 ± 11 47 ± 7 0.09
LA size, mm 27 ± 5 33 ± 6 29± 4 0.02
Mid SA circumferential strain -18.7 ± 1.1 -17.5 ± 0.9 -16.5 ± 0.8 <0.001
Peak diastolic circumferential strain rate (s-1) 118 ± 21 88 ± 18 76 ± 24 <0.001
Presence of LGE (%) 0 8 (50) 3 (23) -
Volume fraction of LGE>2SD (%) 0 3.4 ± 0.4 2.6 ± 0.3 -
Global myocardial T2 SI Ratio 1.5 ± 0.1 1.7 ± 0.3 1.9 ± 0.4 0.03
Volume fraction of oedema by T2 (%) 0 26 (18-39) 20 (13-31) -
Average myocardial T1, ms 961 ± 12 968 ±25 987 ± 26 0.01
Volume fraction of T1>990ms (%) 3 (1-5) 34 (17-55) 41 (23-61) <0.001
ECV (%) 26.5 ± 2.7 30.4 ± 3.1 32.2 ± 4.4 <0.001
MPRI 2.0 ± 0.3 1.6 ± 0.2 1.5 ± 0.5 <0.001
PCr/ATP 2.0 ± 0.3 1.5 ± 0.3 1.4 ± 0.3 <0.001
Cardiac lipid content (%) 0.49 ± 0.37 0.46 ± 0.33 0.58 ± 0.27 0.78
Hepatic lipid content (%) 1.70 ± 0.72 1.46 ± 0.58 2.17 ± 1.02 0.64
Continuous data are mean ± SD unless otherwise indicated. BSA, body surface area; ECV, extracellular volume; LA, left atrium; LGE, late gadolinium enhancement;
LV, left ventricle/ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MPRI,
myocardial perfusion reserve index; PCr/ATP, phosphocreatine to adenosine triphosphate ratio; RPP, rate pressure product; SA, short axis; SI, signal intensity, SLE,
systemic lupus erythematosus
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myocardial fibrosis and oedema. There are no differ-
ences in myocardial lipid content between patients and
controls.
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